Quick Answer
Atea Pharmaceuticals, Inc. reported Operating Income Loss of -$180.89 million for the year ending 2025.
- Atea Pharmaceuticals, Inc. showed an increase of +6.3% in Operating Income Loss from 2024 to 2025.
- This data is from Atea Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 8 years of available data (2018 to 2025), Atea Pharmaceuticals, Inc.'s Operating Income Loss has declined by 1,808.7%.
- Historical annual values: Fiscal year 2025: -$180.89 million | Fiscal year 2024: -$192.95 million | Fiscal year 2023: -$164.16 million | Fiscal year 2022: -$130.65 million | Fiscal year 2021: $138.38 million | Fiscal year 2020: -$11.03 million | Fiscal year 2019: -$14.61 million | Fiscal year 2018: -$9.48 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: